

PLSCR4 Antibody (Center) Blocking peptide
Synthetic peptide
Catalog # BP13974c**Specification**

PLSCR4 Antibody (Center) Blocking peptide - Product InformationPrimary Accession [Q9NRQ2](#)**PLSCR4 Antibody (Center) Blocking peptide - Additional Information****Gene ID** 57088**Other Names**

Phospholipid scramblase 4, PL scramblase 4, Ca(2+)-dependent phospholipid scramblase 4, Cell growth-inhibiting gene 43 protein, TRA1, PLSCR4

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP13974c was selected from the Center region of PLSCR4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

PLSCR4 Antibody (Center) Blocking peptide - Protein Information**Name** PLSCR4**Function**

May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. May play a central role in the initiation of fibrin clot formation, in the activation of mast cells and in the recognition of apoptotic and injured cells by the reticuloendothelial system.

Cellular Location

Membrane; Single-pass type II membrane protein

Tissue Location

Expressed in heart, brain, placenta, lung, liver, kidney, pancreas, spleen, thymus, prostate, testis, uterus, small intestine and colon. Not detected in peripheral blood lymphocytes

PLSCR4 Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

PLSCR4 Antibody (Center) Blocking peptide - Images**PLSCR4 Antibody (Center) Blocking peptide - Background**

PLSCR4 may mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. May play a central role in the initiation of fibrin clot formation, in the activation of mast cells and in the recognition of apoptotic and injured cells by the reticuloendothelial system.

PLSCR4 Antibody (Center) Blocking peptide - References

Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Sahu, S.K., et al. Biochim. Biophys. Acta 1790(10):1274-1281(2009)Py, B., et al. PLoS ONE 4 (3), E5006 (2009) :Shibata, H., et al. J. Biol. Chem. 283(15):9623-9632(2008)Wiedmer, T., et al. Biochim. Biophys. Acta 1467(1):244-253(2000)